Table 1.

IC₉₀ of 4-HPR, ABT-737 and CIN values of ABT-737 at concentrations in combination with 4-HPR

Group	Cell line	Phase of therapy	IC90 (μM)		CIN at each concentration (μM)
			4-HPR	ABT-737	1.25	2.5	5	10
A. Prior to any therapy	CHLA-15	DX	3.7	0.5	0.486	0.349	0.416	0.001
	SMS-KAN	DX	2.4	1.4	0.152	0.086	0.073	0.063
B. At progressive disease during or after therapy	SMS-KCNR	PD	2.3	1	0.342	0.414	0.321	0.382
	SK-N-RA	PD	12.3	>20	0.255	0.402	0.474	0.324
	CHLA-20	PD	10.3	>20	1.458	0.648	0.56	0.161
	LA-N-6	PD	3.2	13.7	-	0.794	1.016	0.425
	SK-N-BE(2)	PD	2.2	12.3	0.827	0.543	0.16	0.058
	CHLA-119	PD*	1.1	15.8	0.619	0.353	0.496	0.109
	CHLA-140	PD*	2.2	0.4	0.521	0.922	0.785	0.86
C. At relapse after myeloablative therapy and bone marrow transplantation	CHLA-79	PD-BMT	8.6	>20	-	1.481	0.817	0.332
	CHLA-136	PD-BMT	11.3	2.9	0.237	0.218	0.209	0.238

Lines in the panel included those established at diagnosis before therapy (DX), at time of progressive disease during or after non-myeloablative therapy (PD), after therapy with 13-cis-RA (PD*), after myeloablative therapy and bone marrow transplantation (PD-BMT).

A CIN less than 0.9 indicates synergism; 0.1, very strong synergism; 0.1 to 0.3, strong synergism; 0.3 to 0.7, good synergism; 0.7 to 0.85, moderate synergism; 0.85 to 0.9, slight synergism; 0.9 to 1.1, addictive; and more than 1.1, antagonism. - Indicates not applicable.